Person:
Martínez-Sellés D Oliveira Soares, Manuel

Loading...
Profile Picture
First Name
Manuel
Last Name
Martínez-Sellés D Oliveira Soares
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Medicina
Department
Medicina
Area
Medicina
Identifiers
UCM identifierORCIDScopus Author IDDialnet ID

Search Results

Now showing 1 - 10 of 10
  • Item
    Coronary angiography in patients without ST-segment elevation following out-of-hospital cardiac arrest. COUPE clinical trial
    (2023) Viana Tejedor, Ana Teresa; Martínez-Sellés D Oliveira Soares, Manuel; Fernández Ortiz, Antonio Ignacio; Pérez Villacastín Domínguez, Julián
    El papel de la coronariografía urgente y angioplastia, si procede, en los pacientes con parada cardiaca extrahospitalaria (PCEH) recuperada que no presentan elevación del segmento ST es controvertido. Nuestro objetivo fue evaluar si la coronariografía urgente y la angioplastia mejoran la supervivencia con buen pronóstico neurológico en esta población. En este ensayo clínico multicéntrico, aleatorizado, abierto, incluimos 69 pacientes supervivientes a una PCEH sin elevación del ST y se aleatorizaron a recibir una coronariografía urgente (CU) o diferida (CD). El objetivo primario de eficacia fue el combinado de supervivencia hospitalaria libre de dependencia. El objetivo de seguridad fue un compuesto de eventos cardiacos mayores, incluyendo muerte, reinfarto, sangrado y arritmias ventriculares. Resultados: Se incluyó a 66 pacientes en el análisis primario (95,7%). La supervivencia hospitalaria fue 62,5% en el grupo CU y 58,8% en el grupo CD (HR = 0,96; IC95%, 0,45-2,09; p = 0,93). La supervivencia hospitalaria con buen pronóstico neurológico fue 59,4% en el grupo CU y 52,9% en el grupo CD (HR = 1,29; IC95%, 0,60-2,73; p = 0,4986). No se encontraron diferencias en los objetivos secundarios, salvo por la incidencia de fracaso renal agudo, que fue más frecuente en el grupo CU (15,6 frente a 0%, p = 0,002) y de infecciones, más prevalentes en el grupo CD (46,9 frente a 73,5%, p = 0,003). Conclusiones: En este estudio aleatorizado de pacientes con una PCEH sin elevación del ST, una coronariografía urgente no fue beneficiosa en términos de supervivencia con buen pronóstico neurológico comparada con una coronariografía diferida.
  • Item
    Temporal Trends in Mechanical Complications of Acute Myocardial Infarction in the Elderly
    (2018) Puerto, Elena; Viana Tejedor, Ana Teresa; Martínez-Sellés D Oliveira Soares, Manuel; Domínguez Pérez, Laura; Moreno, Guillermo; Martín Asenjo, Roberto; Bueno Zamora, Héctor José
    Background: Reperfusion therapy led to an important decline in mortality after ST-segment elevation myocardial infarction (STEMI). Because the rate of cardiogenic shock has not changed dramatically, the authors speculated that a reduction in the incidence or fatality rate of mechanical complications (MCs), the second cause of death in these patients, could explain this decrease. Objectives: This study sought to assess time trends in the incidence, management, and fatality rates of MC, and its influence on short-term mortality in old patients with STEMI. Methods: Trends in the incidence and outcomes of MC between 1988 and 2008 were analyzed by Mantel-Haenszel linear association test in 1,393 consecutive patients ≥75 years of age with first STEMI. Results: Overall in-hospital mortality decreased from 34.3% to 13.4% (relative risk reduction, 61%; p < 0.001). Although the absolute mortality due to MC decreased from 9.6% to 3.3% (p < 0.001), the proportion of deaths due to MC among all deaths did not change (28.1% to 24.5%; p = 0.53). The incidence of MC decreased from 11.1% to 4.3% (relative risk reduction 61%) with no change in their hospital fatality rate over time (from 87.1% to 82.4%; p = 0.66). The proportion of patients undergoing surgical repair decreased from 45.2% to 17.6% (p = 0.04), with no differences in post-operative survival (from 28.6% to 33.3%; p = 0.74). Conclusions: Although the incidence of MC has decreased substantially since the initiation of reperfusion therapy in elderly STEMI patients, this reduction was proportional to other causes of death and was not accompanied by an improvement in fatality rates, with or without surgery. MCs are less frequent but remain catastrophic complications of STEMI in these patients.
  • Item
    Interatrial Block, Bayés Syndrome, Left Atrial Enlargement, and Atrial Failure
    (Journal of Clinical Medicine, 2023) Bejarano Arosemena, Roberto; Martínez-Sellés D Oliveira Soares, Manuel
    Interatrial block (IAB) is defined by the presence of a P-wave ≥120 ms. Advanced IAB is diagnosed when there is also a biphasic morphology in inferior leads. The cause of IAB is complete block of Bachmann’s bundle, resulting in retrograde depolarization of the left atrium from areas near the atrioventricular junction. The anatomic substrate of advanced IAB is fibrotic atrial cardiomyopathy. Dyssynchrony induced by advanced IAB is frequently a trigger and maintenance mechanism of atrial fibrillation (AF) and other atrial arrhythmias. Bayés syndrome is characterized by the association of advanced IAB with atrial arrhythmias. This syndrome is associated with an increased risk of stroke, dementia, and mortality. Advanced IAB frequently produces an alteration of the atrial architecture. This atrial remodeling may promote blood stasis and hypercoagulability, triggering the thrombogenic cascade, even in patients without AF. In addition, atrial remodeling may ultimately lead to mechanical dyssynchrony and enlargement. Atrial enlargement is usually the result of prolonged elevation of atrial pressure due to various underlying conditions such as IAB, diastolic dysfunction, left ventricular hypertrophy, valvular heart disease, hypertension, and athlete’s heart. Left atrial enlargement (LAE) may be considered present if left atrial volume indexed to body surface is > 34 mL/m2; however, different cut-offs have been used. Finally, atrial failure is a global clinical entity that includes any atrial dysfunction that results in impaired cardiac performance, symptoms, and decreased quality of life or life expectancy.
  • Item
    Current and Future Use of Artificial Intelligence in Electrocardiography
    (Current and Future Use of Artificial Intelligence in Electrocardiography, 2023) Martínez-Sellés D Oliveira Soares, Manuel; Manuel Marina-Breysse
    Artificial intelligence (AI) is increasingly used in electrocardiography (ECG) to assist in diagnosis, stratification, and management. AI algorithms can help clinicians in the following areas: (1) interpretation and detection of arrhythmias, ST-segment changes, QT prolongation, and other ECG abnormalities; (2) risk prediction integrated with or without clinical variables (to predict arrhythmias, sudden cardiac death, stroke, and other cardiovascular events); (3) monitoring ECG signals from cardiac implantable electronic devices and wearable devices in real time and alerting clinicians or patients when significant changes occur according to timing, duration, and situation; (4) signal processing, improving ECG quality and accuracy by removing noise/artifacts/interference, and extracting features not visible to the human eye (heart rate variability, beat-to-beat intervals, wavelet transforms, sample-level resolution, etc.); (5) therapy guidance, assisting in patient selection, optimizing treatments, improving symptom-to-treatment times, and cost effectiveness (earlier activation of code infarction in patients with ST-segment elevation, predicting the response to antiarrhythmic drugs or cardiac implantable devices therapies, reducing the risk of cardiac toxicity, etc.); (6) facilitating the integration of ECG data with other modalities (imaging, genomics, proteomics, biomarkers, etc.). In the future, AI is expected to play an increasingly important role in ECG diagnosis and management, as more data become available and more sophisticated algorithms are developed.
  • Item
    Nosocomial infections in adult patients supported by extracorporeal membrane oxygenation in a cardiac intensive care unit
    (Microorganisms, 2023) Mornese Pinna, Simone; Sousa Casasnovas, Iago; Olmedo, María; Machado, Marina; Juàrez Fernández, Miriam; Devesa Cordero, Carolina; Galar, Alicia; Álvarez Uría, Ana; Fernández Avilés, Francisco; García Carreño, Jorge; Martínez-Sellés D Oliveira Soares, Manuel; De Rosa, Francesco Giuseppe; Corcione, Silvia; Bouza Santiago, Emilio; Muñoz García, Patricia Carmen; Valerio Minero, Maricela
    The use of venoarterial (VA) extracorporeal membrane oxygenation therapy (ECMO) in patients admitted to cardiac intensive care units (CICU) has increased. Data regarding infections in this population are scarce. In this retrospective study, we analyzed the risk factors, outcome, and predictors of in-hospital mortality due to nosocomial infections in patients with ECMO admitted to a single coronary intensive care unit between July 2013 and March 2019 treated with VA-ECMO for >48 h. From 69 patients treated with VA-ECMO >48 h, (median age 58 years), 29 (42.0%) patients developed 34 episodes of infections with an infection rate of 0.92/1000 ECMO days. The most frequent were ventilator-associated pneumonia (57.6%), tracheobronchitis (9.1%), bloodstream infections (9.1%), skin and soft tissue infections (9.1%), and cytomegalovirus reactivation (9.1%). In-hospital mortality was 47.8%, but no association with nosocomial infections was found (p = 0.75). The number of days on ECMO (OR 1.14, 95% CI 1.01–1.30, p = 0.029) and noninfectious complications were higher in the infected patients (OR: 3.8 95% CI = 1.05–14.1). A higher baseline creatinine value (OR: 8.2 95% CI = 1.12–60.2) and higher blood lactate level at 4 h after ECMO initiation (OR: 2.0 95% CI = 1.23–3.29) were significant and independent risk factors for mortality. Conclusions: Nosocomial infections in medical patients treated with VA-ECMO are very frequent, mostly Gram-negative respiratory infections. Preventive measures could play an important role for these patients.
  • Item
    Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction
    (Journal of Clinical Medicine, 2023) Vicent, Lourdes; Álvarez García, Jesús; Vazquez Garcia, Rafael; González Juanatey, José R.; Rivera, Miguel; Segovia, Javier; Pascual Figal, Domingo; Bover, Ramón; Worner, Fernando; Fernández Avilés, Francisco; Ariza Sole, Albert; Martínez-Sellés D Oliveira Soares, Manuel
    Our aim was to determine the prognostic impact of coronary artery disease (CAD) on heart failure with reduced ejection fraction (HFrEF) mortality and readmissions. From a prospective multicenter registry that included 1831 patients hospitalized due to heart failure, 583 had a left ventricular ejection fraction of <40%. In total, 266 patients (45.6%) had coronary artery disease as main etiology and 137 (23.5%) had idiopathic dilated cardiomyopathy (DCM), and they are the focus of this study. Significant differences were found in Charlson index (CAD 4.4 ± 2.8, idiopathic DCM 2.9 ± 2.4, p < 0.001), and in the number of previous hospitalizations (1.1 ± 1, 0.8 ± 1.2, respectively, p = 0.015). One-year mortality was similar in the two groups: idiopathic DCM (hazard ratio [HR] = 1), CAD (HR 1.50; 95% CI 0.83–2.70, p = 0.182). Mortality/readmissions were also comparable: CAD (HR 0.96; 95% CI 0.64–1.41, p = 0.81). Patients with idiopathic DCM had a higher probability of receiving a heart transplant than those with CAD (HR 4.6; 95% CI 1.4–13.4, p = 0.012). The prognosis of HFrEF is similar in patients with CAD etiology and in those with idiopathic DCM. Patients with idiopathic DCM were more prone to receive heart transplant.
  • Item
    Comparison of a polypharmacy-based scale with Charlson comorbidity index to predict 6-month mortality in chronic complex patients after an ED visit
    (British Journal of Clinical Pharmacology, 2022) Enríquez Gómez, Andrés; Ortega Navarro, María Cristina; Fernández Cordón, Clara; Díez Villanueva, Pablo; Martínez-Sellés D Oliveira Soares, Manuel; De Lorenzo Pinto, Ana; Miguel Yanes, José María De
    Aims: The aim of this study was to test whether a newly designed polypharmacy-based scale would perform better than Charlson's Comorbidity Index (CCI) to predict outcomes in chronic complex adult patients after a reference Emergency Department (ED) visit. Methods: We built a polypharmacy-based scale with prespecified drug families. The primary outcome was 6-month mortality after the reference ED visit. Predefined secondary outcomes were need for hospital admission, 30-day readmission, and 30-day and 90-day mortality. We evaluated the ability of the CCI and the polypharmacy-based scale to independently predict 6-month mortality using logistic regression, receiver operating characteristic (ROC) curves, and cumulative survival curves using Kaplan-Meier estimates and the log-rank test for three-category distributions of the polypharmacy-based scale and the CCI. Finally, we sought to replicate our results in two different external validation cohorts. Results: We included 201 patients (53.7% women, mean age = 81.4 years), 162 of whom were admitted to the hospital at the reference ED visit. In separate multivariable analyses accounting for gender, age and main diagnosis at discharge, both the polypharmacy-based scale (P < .001) and the CCI (P = .005) independently predicted 6-month mortality. The polypharmacy-based scale performed better in the ROC analyses (area under the curve [AUC] = 0.838, 95% confidence interval [CI] = 0.780-0.896) than the CCI (AUC = 0.628, 95% CI = 0.548-0.707). In the 6-month cumulative survival analysis, the polypharmacy-based scale showed statistical significance (P < .001), whereas the CCI did not (P = .484). We replicated our results in the validation cohorts. Conclusions: Our polypharmacy-based scale performed significantly better than the CCI to predict 6-month mortality in chronic complex patients after a reference ED visit.
  • Item
    Trends in cardiogenic shock management and prognostic impact of type of treating center
    (Revista Española de Cardiología, 2020) Sánchez Salado, José C.; Bernal, José Luis; Fernández Pérez, Cristina; Martínez-Sellés D Oliveira Soares, Manuel; Viana Tejedor, Ana Teresa; Bueno Zamora, Héctor José; Elola, Javier
    Las guías de práctica clínica actuales recomiendan centralizar la atención de los pacientes con shock cardiogénico en centros de alto volumen. El objetivo de este estudio era evaluar la asociación entre las características hospitalarias, incluida la disponibilidad de una unidad de cuidados intensivos cardiológicos y los resultados en los pacientes con shock cardiogénico relacionado con infarto de miocardio con elevación del segmento ST (IAMCEST). Métodos: Los episodios de alta con diagnóstico de SC relacionado con IAMCEST entre 2003 y 2015 fueron seleccionados del Conjunto Mínimo de Datos del Sistema Nacional de Salud español. Los centros se clasificaron en función de la disponibilidad de servicio de cardiología, laboratorio de hemodinámica, servicio de cirugía cardiaca y unidad de cuidados intensivos cardiológicos. El resultado principal medido fue la mortalidad intrahospitalaria. Resultados: Se identificaron un total de 19.963 episodios. La edad media era de 73,4 años. La proporción de pacientes con SC tratados en hospitales con laboratorio de hemodinámica y servicio de cirugía cardíaca aumentó del 38,4% en 2005 al 52,9% en 2015 (p < 0,005). Las tasas de mortalidad bruta y ajustada por riesgo disminuyeron con el tiempo, del 82% al 67,1%, y del 82,7% al 66,8%, respectivamente (ambas P < 0,001). La revascularización coronaria, ya fuera percutánea o mediante bypass coronario, se asoció de forma independiente a un menor riesgo de mortalidad (OR 0,29 y 0,25; ambas p < 0,001, respectivamente). La disponibilidad de cuidados intensivos cardiológicos se asoció a tasas de mortalidad ajustadas más bajas (65,3% frente a 72%; P < 0.001). Conclusiones: La proporción de pacientes con SC relacionada con IAMCEST tratados en centros altamente especializados aumentó mientras que la mortalidad disminuyó durante el período de estudio. Los mejores resultados se asociaron a la mayor realización de procedimientos de revascularización y al acceso a unidades de cuidados intensivos cardiológicos a lo largo del tiempo.
  • Item
    Prognostic Implications of High-Degree Atrio-Ventricular Block in Patients with Acute Myocardial Infarction in the Contemporary Era
    (Journal of Clinical Medicine, 2023) Velásquez Rodríguez, Jesús; Vicent, Lourdes; Díez Delhoyo, Felipe; Valero Masa, María Jesús; Bruña, Vanesa; Sousa Casasnovas, Iago; Juárez Fernández, Miriam; Fernández-Avilés Díaz, Francisco Jesús; Martínez-Sellés D Oliveira Soares, Manuel
    Background: High-degree atrioventricular block (HAVB) is a known complication of ST-segment elevation myocardial infarction (STEMI). We aimed to determine the prevalence and prognostic impact of HAVB in a contemporary cohort of STEMI. Methods: Data were collected from the DIAMANTE registry that included STEMI patients admitted to our cardiac intensive care unit treated with urgent reperfusion. We studied the clinical characteristics and evolution in patients with and without HAVB at admission. Results: From 1109 consecutive patients, HAVB was documented in 95 (8.6%). The right coronary artery was the culprit vessel in 84 patients with HAVB (88.4%). The independent predictors of HAVB were: male sex (OR 1.9, 95% CI 1.2–2.9), age (OR 1.03, 95% CI 1.01–1.05), involvement of right coronary artery (OR 12.4, 95% CI 7.6–20.2), and creatinine value (OR 1.5, 95% CI 1.1–2.0). A transient percutaneous pacemaker was used in 37 patients with HAVB (38.9%). Patients with HAVB had higher mortality that patients without HAVB (15.8% vs. 4.1%, p < 0.001); however, in multivariate analysis, HAVB was not an independent predictor of in-hospital mortality. Conclusions: HAVB was seen in 9% of STEMI patients and was particularly frequent in elderly males with renal failure. Patients with HAVB had a poor prognosis during hospitalization, but HAVB was not an independent predictor of in-hospital mortality.
  • Item
    Survey on Cardiogenic Shock and the Use of ECMO and Impella in Spanish Cardiac Critical Care Units
    (Journal of Vascular Diseases, 2023) García Carreño, Jorge; Martínez-Solano, Jorge; Sousa, Iago; Juárez-Fernández, Miriam; Martínez-Sellés D Oliveira Soares, Manuel
    Background: Previous studies suggest variability in the management of cardiogenic shock (CS). Methods: An anonymous survey was sent to Spanish hospitals. Results: We obtained 50 answers, mainly from cardiologists (36–72%). The annual average of ECMOs is 16.7 ± 11.3 applications in CS patients and of Impellas is 8.7 ± 8.3 applications in CS patients. Intra-aortic balloon counterpulsation is used in the majority of CS ECMOs (31–62%), and Impella is used in 7 (14%). In 36 (72%) cases, ECMO is used as a treatment for cardiac arrest. In 10 cases, ECMO removal is percutaneous (20%). In 25 (50%) cases, age is a relative contraindication; 17 have a mobile ECMO team (34%); and 23 (46%) have received ECMO patients from other centers in the last year. Pre-purged ECMO is only used in 16 (32%). ECMO implantation is carried out under ultrasound guidance in 31 (62%), only with angiography in 3 (6%) and with both in 11 (22%). The Swan–Ganz catheter is used routinely in 8 (16%), only in doubtful cases in 24 (48%), and in most cases in 8 (16%). The ECMO awake strategy is used little or not at all in 28 (56%), in selected cases in 17 (34%), and routinely in 5 (10%). Conclusion: Our study shows a huge variation in the management of patients with CS.